Status:

COMPLETED

Ventricular Tachycardia (VT) Ablation or Escalated Drug Therapy

Lead Sponsor:

John Sapp

Collaborating Sponsors:

Abbott Medical Devices

Biosense Webster, Inc.

Conditions:

Recurrent Ventricular Tachycardia

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

This study will compare aggressive antiarrhythmic therapy to catheter ablation for ventricular tachycardia in patients who have suffered prior myocardial infarction. The purpose of this study is to ev...

Detailed Description

This is a multicentre, parallel group, two arm, unblinded, randomized clinical trial to compare two management strategies for patients with ischemic heart disease and recurrent ICD therapy despite at ...

Eligibility Criteria

Inclusion

  • Prior Myocardial Infarction
  • An implantable defibrillator
  • One of the following VT events (within the past 3 months):
  • greater than or equal to 3 episodes of symptomatic VT treated with ATP
  • greater than or equal to 1 appropriate ICD shock
  • greater than or equal to 3 VT episodes within 24 hours
  • sustained VT below detection rate of the ICD documented by ECG
  • "Failed" first-line antiarrhythmic drug therapy as defined by one of:
  • Appropriate ICD therapy or sustained VT occurred while patient was taking amiodarone (stable dose \>/= 2 weeks)
  • Appropriate ICD therapy or sustained VT occurred on another antiarrhythmic drug (stable dose \>/= 2 weeks)

Exclusion

  • Active ischemia (acute thrombus, dynamic ST elevation on ECG) or another reversible cause of VT (eg. electrolyte abnormalities, drug induced arrhythmia)
  • Are known to be ineligible to take amiodarone (eg. active hepatitis, current hyperthyroidism, pulmonary fibrosis, known allergy)
  • Are ineligible for ablation (left ventricular thrombus, implanted mechanical aortic and mitral valves)
  • Renal Failure (creatinine clearance \< 15 ml/min)
  • Current NYHA functional class IV heart failure or CCS Functional Class IV angina
  • Recent ST elevation myocardial infarction (\< 1 month)
  • Recent coronary bypass surgery (\< 3 mon) or recent PCI (\< 1 mon)
  • Pregnant
  • prior ablation for ventricular tachycardia
  • A systemic illness likely to limit survival to \< 1 year
  • Unable or unwilling to provide informed consent

Key Trial Info

Start Date :

May 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2015

Estimated Enrollment :

260 Patients enrolled

Trial Details

Trial ID

NCT00905853

Start Date

May 1 2009

End Date

December 1 2015

Last Update

July 11 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

QEII Health Sciences Centre

Halifax, Nova Scotia, Canada, B3H 3A7